🔴Transcatheter Tricuspid Valve Replacement ⤵️ JACC State-of-the-Art #2025Review #OpenAccess 🔹sciencedirect.com/science/articl… #POCUS #Cardiology #FOAMed #MedEd #medstudent #paramedic #Cardiology #CardioEd #medtwitter #meded #CardioTwitter #cardiotwiteros #MedX

Transcatheter Tricuspid Valve Replacement with the EVOQUE system has been recently approved for commercial use in the U.S. and its adoption is increasing. Paravalvular leaks (PVL) post-Evoque have been poorly characterized and their management may be challenging. Just published

In the SCOPE I trial, patients with frailty had a similar improvement in patient-reported health status measures after TAVR, but a higher risk of unfavorable outcomes throughout 3 years of follow-up. authors.elsevier.com/sd/article/S27…

Tricuspid Regurgitation Disease Stages and Treatment Outcomes After Transcatheter Tricuspid Valve Repair T-TEER was associated with 1-year survival at intermediate stage disease but not at early or advanced disease stages jacc.org/doi/10.1016/j.…

Moderate AS is assoc w/ ⬆️ risk but is a heterogeneous group. Careful phenotyping may ID pts who benefit from valvular intervention, while others may not, requiring a larger sample size w/ balanced groups to confirm its effect jacc.org/doi/10.1016/j.… #JACCIMG #vhdAS Tom Marwick

In the EXPANDed studies, pts with moderate secondary mitral regurgitation (SMR) treated with M-TEER had improvements similar to subjects with severe SMR in #QoL and positive LV remodeling at 1 year. jacc.org/doi/10.1016/j.… #JACCHF #HeartFailure #TEER #HeartMonth Dr. Gilbert Tang

New study summarizing results of ELASTA procedure - transcatheter bailout strategy for failed M-TEER: 👉100% Procedural success and 30d survival BUT 👉15% risk of stroke / relevant PVR Congratulations to the authors! Daryoush Samim Fabien Praz

#SGLT2 inhibitors may slow the progression of nonsevere aortic stenosis, according to a study published in #JACCINT. Learn more: bit.ly/4hOrOmA #vhdAS #cvVHD JACC Journals

魔法の薬なん？

💡 This #ValveDiseaseDay, take a step towards advancing your knowledge and patient care at #NYValves2025! 🫀 Join global experts in structural heart medicine for an unparalleled educational experience. Dive into live-case demonstrations, interactive debates, and hands-on

Determining kidney function-specific thresholds for N-terminal pro-B-type natriuretic peptide in HF risk prediction among CKD NT-proBNP levels must be interpreted in the context of kidney function, as eGFR-specific thresholds provide superior HF risK heart.bmj.com/content/early/…

A huge step forward for our transeptal MV repair program: First #ChordArt CoreMedic performed, one of the few FIH in the world. Mild MR, no residual prolapse, no limitations in future options. Real cutting edge technology! Rodrigo Estévez José Antonio Baz Andrés Íñiguez Romo Alberto Weber

Just published in JACC Journals : Severe trans- & para-valvular MR post-healed endocarditis managed with closure of mitral annulus cavity with a nitinol occluder then Tendyne mitral valve implantation It won best case at #PCRLV 2024. Fabien Praz Domenico Angellotti Selim Mosbahi, MD

#ACC25 Day 2, here is the summary of today’s trials (I haven’t included the follow-up extensions of Evolut Low Risk, Triluminate, and FAME 3). Today, I counted at least 2 NEJM, 4 Lancet, 1 Nature, 1 JAMA, 1 Circulation, and 1 JACC. 1. MIGHTy-Heart = In-home paramedic visits for

2Yr TRILUMINATE shows ⬇️ in annualized HFH at 24 months in Device group (p=0.02) despite crossovers! bit.ly/2YrTRILUMINATE #ACC25 Circulation American College of Cardiology European Society of Cardiology Ritu Thamman MD

Excited to share our latest review on imaging in TR and more! Grateful to RTHahnMD and João Cavalcante for the opportunity to contribute to this important project. #ACC25 #JACCIMG

Join us for a free CSI webinar “Current Challenges of Tricuspid Regurgitation” Friday June 6. Register now! bit.ly/CSI_TR-Challen… Anna Sannino MD PhD FASE Denisa Muraru Joanna Bartkowiak Sean Pinney Fabien Praz #CSIFoundation #CSIvirtual CSI Congress

🔥 Just Announced: Late-Breaking Research at #NYValves2025! 12 game-changing clinical trials that will reshape your practice. ow.ly/Q1u350WakNO Not registered yet? Get a front-row seat to the future of structural heart care! ow.ly/ZlB950WakNR #CardioX

Are you performing right cath after TTVR? EJHF: First insights into the impact of TR elimination on right heart: Immediate RAP reduction ⬇️ Increased systolic RV/PA pressure⬆️ and PAPi ⬆️ Data From Bern by Fabien Praz 🔗 doi.org/10.1002/ejhf.3… EJHF Editor-in-Chief #CardioTwitter